类有机物
结肠镜检查
结直肠癌
离体
医学
病理
体内
生物
内科学
细胞生物学
癌症
生物技术
作者
Hong Chen,Yu‐Ping Yang,Jinsen Shi,Ting Yan,Jun Wang,Yuning Yang,Qin Lu,Hailan Feng,Jian Du,Zhiyun Cao,Nathaniel Weygant
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2024-05-01
卷期号:24 (5): 546-555
标识
DOI:10.2174/0115680096263866231024112120
摘要
Background: Patient-derived organoids (PDOs) are ex vivo models that retain the functions and characteristics of individualized source tissues, including a simulated tumor microenvironment. However, the potential impact of undiscovered differences between tissue sources on PDO growth and progression remains unclear. Objective: This study aimed to compare the growth and condition of PDO models originating from surgical resection and colonoscopy and to provide practical insights for PDO studies. Methods: Tissue samples and relevant patient clinical information were collected to establish organoid models. PDOs were derived from both surgical and colonoscopy tissues. The growth of the organoids, including their state, size, and success rate of establishment, was recorded and analyzed. The activity of the organoids at the end stage of growth was detected using calcein-AM fluorescence staining. Results: The results showed that the early growth phase of 2/3 colonoscopy-derived organoids was faster compared to surgical PDOs, with a growth difference observed within 11-13 days of establishment. However, colonoscopy-derived organoids exhibited a diminished growth trend after this time. There were no significant differences observed in the terminal area and quantity between the two types of tissue-derived organoids. Immunofluorescence assays of the PDOs revealed that the surgical PDOs possessed a denser cell mass with relatively higher viability than colonoscopy-derived PDOs. Conclusion: In the establishment of colorectal patient-derived organoids, surgically derived organoids require a slightly longer establishment period, while colonoscopy-derived organoids should be passaged prior to growth inhibition to preserve organoid viability.
科研通智能强力驱动
Strongly Powered by AbleSci AI